2011

The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.

All pharma companies face a communications crisis that rests on the changing role of the medical sales representative. This evolution has a direct impact on the obligations of the pharma marketing organizations to be both proactive and responsive in helping to protect their organizations from the threat of non-compliance. What can marketing do? This article offers a few thoughts from a physician's point.

Welcome to Volume 10, Issue #8 (28 APRIL 2011) of Pharma Marketing News.

Welcome to Volume 10, Issue #10 (8 JUNE 2011) of Pharma Marketing News.

This article summaries research data exploring why physicians interested in using online peer-to-peer social communities outnumber by 2 to 1 physicians who are actually using them. Includes suggestions for what these communities must do in order to provide more value to physicians.

Opening the Door to FDA-Compliant Branded Tweets: Deck.ly has enormous potential for pharmaceutical marketers who have been chaffing at the bit to post meaningful branded messages via Twitter but who have been stymied by lack of guidance from FDA regarding how to provide fair balance within the 140-character limit of Twitter.

Welcome to Volume 10, Issue #8 (28 APRIL 2011) of Pharma Marketing News.

Welcome to Volume 10, Issue #5 (10 MARCH 2011) of Pharma Marketing News.

Lipitor Won't Go Gentle Into that Good Generic Night. Pfizer is taking a number of steps to protect it's Lipitor franchise and it hopes that many patients currently taking Lipitor will remain loyal to the brand.

How much money the pharmaceutical industry spends on Internet marketing, direct-to-consumer advertising, and physician detailing are always topics of interest and 2010 was no exception. 2010 was, however, a turning point in bringing more attention to payments made to physicians for speaking, consulting, and research.